1. Home Page
  2. About the OSUCCC – James
  3. Publications and Reports
  4. Magazines and Publications
  5. Frontiers
  6. 2010
  7. Fall
2010

Frontiers Fall 2010

This has been an extraordinary summer at The Ohio State University. In June, we broke ground for construction of a 17-story patient tower that will house a new and much larger James Cancer Hospital and Solove Research Institute.

Frontiers Fall 2010

    Summer of Progress: Construction begins, the CARE Act is introduced, The James turns 20

    This has been an extraordinary summer at The Ohio State University. In June, we broke ground for construction of a 17-story patient tower that will house a new and much larger James Cancer Hospital and Solove Research Institute. It will be the centerpiece of Ohio State’s $1 billion ProjectONE medical center expansion.

    In July, we helped introduce a piece of landmark federal legislation, the Cancer Centers Assistance for Renovations and Expansion Act of 2010, or CARE Act (HR 5861). The act will provide low-interest loans to fund the expansion of cancer centers and comprehensive cancer centers, as designated by the National Cancer Institute (NCI). These loans will pay the capital costs of projects that improve a center’s research, prevention or patient-care infrastructure.

    Given the present economic climate, this bill will help centers obtain the resources they need to further cancer research and accommodate the rising number of cancer patients in our aging population.

    Our thanks to the bill’s sponsor, Rep. Mary Jo Kilroy (OH-15), and its co-sponsors, Reps. Tim Ryan (OH-17), Michael E. Capuano (MA-8), Carolyn Maloney (NY-14) and Kendrick Meek (FL-17).

    Also in July, our faculty and staff celebrated the 20-year anniversary of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. We came together to reflect on our two decades of effort to provide exceptional cancer care at The James, and we looked to the future and to meeting the challenge of creating a cancer-free world.

    Finally, we send our best to Dr. John Niederhuber, who in July stepped down as NCI director after guiding the agency through several difficult budget years while keeping cancer research moving forward. And we welcome Dr. Harold Varmus in his new role as the NCI’s 14th director.

    View the complete issue in PDF format

    Accrual Boosting

    In 2007, we at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) conducted a comprehensive review of patient participation in therapeutic clinical trials and discovered that our accrual rate had flatlined at about 14 percent per year.

    'Grow or Go' Switch

    Researchers at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) have discovered a mechanism that regulates the behavior of glioblastoma multiforme cells.

    Vicious Circle

    Researchers at the OSUCCC – James have identified a self-feeding “vicious circle” of molecules that keeps acute leukemia cells alive and growing. Their findings suggest a new strategy for treating acute myeloid leukemia (AML) by targeting this molecular network and lowering the amount of a protein called KIT.

    Papilloma Predictor

    The presence of human papilloma virus (HPV) in oropharyngeal tumors is the most important predictor of patient survival, according to a study at the OSUCCC – James.

    Up for the Challenge

    An animal study led by researchers at the OSUCCC-James shows that living in an environment rich with physical, mental and social stimulation – a setting that causes mild stress – may curb cancer growth.

    Invaluable Intervention

    A psychological intervention program for breast cancer patients can reduce the risk of dying if the cancer recurs, new research shows.

    Rewire Act

    A multicenter study led by scientists at the OSUCCC – James shows that microRNA (miRNA) molecules work together in single, well-connected networks to control functions in healthy cells, but in cancer cells the networks are rewired and fragmented.

    Of Note

    A listing of the recent recognitions of OSUCCC – James physicians and researchers.

    Deep Thinking

    Leukemia research reached a milestone in 1994 with the discovery of the MLL PTD gene mutation in patients with cytogenetically normal acute myeloid leukemia (CN-AML).

    One for All

    Mutations in a gene called BLM cause Bloom syndrome, a rare autosomal recessive, chromosome-breakage disorder characterized by small stature, sun-sensitivity, immune deficiency and predisposition to multiple cancers.

    Signature Work

    Men who have been diagnosed with cancer that is thought to be contained in the prostate are benefiting from an evolution toward integrated multidisciplinary care backed by research that will yield more accurate prognoses and determine better treatment plans.

    ProjectONE

    A new era of cancer care and research at The Ohio State University began June 18th when the University broke ground for ProjectONE, a $1 billion initiative that includes construction of a 17-story medical tower that will house a reimagined James Cancer Hospital and Solove Research Institute and an equally innovative critical care hospital.

    Riders Reflect on Pelotonia 2010

    Some 4,047 riders participated in the 2010 Pelotonia bicycling event held Aug. 20-22 to raise money for cancer research at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

    Pelotonia

    Last year’s inaugural Pelotonia cycling tour attracted 2,265 riders and raised more than $4.5 million for cancer research at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James).